Pirarubicin
Pirarubicin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | â | 7 | 5 | 1 | 2 | 15 |
| Lymphoma | D008223 | â | C85.9 | â | 3 | â | 1 | â | 4 |
| T-cell lymphoma | D016399 | â | â | â | 1 | â | 1 | â | 2 |
| T-cell lymphoma peripheral | D016411 | â | â | â | 1 | â | 1 | â | 2 |
| Multiple myeloma | D009101 | â | C90.0 | â | â | â | 1 | â | 1 |
| Plasma cell neoplasms | D054219 | â | â | â | â | â | 1 | â | 1 |
| Large-cell lymphoma anaplastic | D017728 | â | C84.6 | â | â | â | 1 | â | 1 |
| Immunoblastic lymphadenopathy | D007119 | EFO_1001350 | C86.5 | â | â | â | 1 | â | 1 |
| Enteropathy-associated t-cell lymphoma | D058527 | â | C86.2 | â | â | â | 1 | â | 1 |
| Panniculitis | D015434 | â | M79.3 | â | â | â | 1 | â | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | D006528 | â | C22.0 | â | 8 | 7 | â | 8 | 21 |
| Carcinoma | D002277 | â | C80.0 | â | 11 | 5 | â | 6 | 20 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | â | 4 | 5 | â | 7 | 14 |
| Sarcoma | D012509 | â | â | â | 3 | 1 | â | â | 3 |
| Therapeutic chemoembolization | D016461 | â | â | â | â | 1 | â | 1 | 2 |
| Progression-free survival | D000077982 | â | â | â | 1 | 1 | â | â | 1 |
| Ablation techniques | D055011 | â | â | â | â | 1 | â | â | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | â | â | â | 4 | â | â | 1 | 5 |
| Transitional cell carcinoma | D002295 | â | â | â | 4 | â | â | â | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | â | C91.0 | â | 2 | â | â | â | 2 |
| Triple negative breast neoplasms | D064726 | â | â | 1 | 1 | â | â | â | 2 |
| Urinary bladder neoplasms | D001749 | â | C67 | â | 1 | â | â | 1 | 2 |
| Osteosarcoma | D012516 | â | â | â | 2 | â | â | â | 2 |
| Neoadjuvant therapy | D020360 | â | â | â | 1 | â | â | â | 1 |
| Antineoplastic combined chemotherapy protocols | D000971 | â | â | â | 1 | â | â | â | 1 |
| Leukemia | D007938 | â | C95 | â | 1 | â | â | â | 1 |
| Lymphoid leukemia | D007945 | â | C91 | â | 1 | â | â | â | 1 |
Show 7 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Radiofrequency ablation | D000078703 | â | â | â | â | â | â | 1 | 1 |
| Catheter ablation | D017115 | â | â | â | â | â | â | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | â | â | â | â | 1 | 1 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | â | â | â | â | 1 | 1 |
| Maternal death | D063130 | â | â | â | â | â | â | 1 | 1 |
| Systemic racism | D000091722 | â | â | â | â | â | â | 1 | 1 |
| Psychological well-being | D000092862 | â | â | â | â | â | â | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pirarubicin |
| INN | pirarubicin |
| Description | Pirarubicin (INN) is an anthracycline drug.
An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.
|
| Classification | Small molecule |
| Drug class | antineoplastic antibiotics (daunorubicin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1 |
Identifiers
| PDB | â |
| CAS-ID | 72496-41-4 |
| RxCUI | â |
| ChEMBL ID | CHEMBL2354444 |
| ChEBI ID | â |
| PubChem CID | 3033521 |
| DrugBank | DB11616 |
| UNII ID | D58G680W0G (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,662 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,553 adverse events reported
View more details
Š 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use